2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1000

Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
Abstract Number: 2125

Comparison Of The Effectiveness Of Local Anesthetic and Corticosteroid Injections For The Treatment Of Piriformis Syndrome
Abstract Number: 1046

Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Abstract Number: 2238

Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Abstract Number: 1123

Comparison Of The Performance Of The BASRI and Msasss In Patients With Early Inflammatory Back Pain From The DESIR Cohort
Abstract Number: 2473

Comparison Of The Two Subtypes Of Axial Spondyloarthritis Patients Fulfilling The Imaging Arm Based On Radiographic and MRI Findings
Abstract Number: 2462

Comparison Of Tumor Necrosis Factor Inhibitor Use For Ankylosing Spondylitis At University Rheumatology Clinics In Scotland and Oregon
Abstract Number: 222

Comparison Of Whole Body Versus Targeted Magnetic Resonance Imaging For Assessing Disease Activity and Damage In Idiopathic Inflammatory Myopathies
Abstract Number: 201

Comparison To Organisational Models For EARLY Rheumatoid Arthritis Management: Routine Care Versus EARLY Arthritis Clinic
Abstract Number: 981

Competency and Confidence In Musculoskeletal Medicine For The First Graduating Class Of a New Medical School
Abstract Number: 1865

Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Abstract Number: 1765

Complement Component C5a Permits The Co-Existence Of Pathogenic Th17 Cells and Type I Interferon In Lupus
Abstract Number: 20

Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 2254

Complementary and Alternative Medicine in Rheumatoid Arthritis – Persistently High Use Over the Past Decade Despite Advent of Biologics
Abstract Number: 2770

Complex Functional Effects Within The HLA Contribute To Sjögren’s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].